Elevated plasma levels of lipoprotein(a), Lp(a), represent a major, inherited risk factor for coronary heart disease, although the mechanism of its action remains unknown. Lp(a) is distinguished from the related LDL particle by the addition of apolipoprotein(a), apo(a). The presence of this large glycoprotein is likely to affect the binding of the particle to the LDL receptor and/or other receptors which may contribute to the atherogenic potential of Lp(a). Here we demonstrate the binding to macrophages of Lp(a) and pure recombinant apo(a) protein, via a specific, high-affinity receptor. This binding could lead to foam cell formation and the localization of Lp(a) to atherosclerotic plaques. (J. Clin. Invest. 1991. 87:767-771.)
Introduction
Plasma levels of lipoprotein(a), Lp(a),' correlate strongly with atherosclerosis, and elevated Lp(a) is an independent risk factor for coronary heart disease (see reference 1 for review). Plasma Lp(a) levels are essentially determined by inheritance and are relatively resistant to diet and drug manipulations. Lp(a) closely resembles LDL in lipid composition and the presence of apolipoprotein B-100 (apo B-100), but also contains a highly glycosylated protein, apolipoprotein(a), apo(a), covalently linked to apo B-100 (1) . The presence of this additional charged moiety could have an effect on the binding ofthe particle to receptors which are significant in the metabolism of LDL. Sequence determination revealed that apo(a) contains remarkable similarity to plasminogen, consisting primarily of numerous repeats which resemble the fourth kringle domain of plasminogen (2, 3) . Apo(a) is a large glycoprotein exhibiting numerous size isoforms ranging from -400 to 800 kD which are due to differing numbers of kringle repeats (4) (5) (6) . The presence of N-and 0-linked glycosylation sites in each kringle give apo(a) a high carbohydrate content and negative charge (3, 7, 8) . Recently we have cloned and expressed in cultured mammalian cells a recombinant apo(a) isoform that has a predicted 1. Abbreviations used in this paper: apo(a), apolipoprotein(a), apo B-100, apolipoprotein B-100; Lp(a), lipoprotein(a).
Mr of 250,000 but migrates on reducing SDS-PAGE at -500,000 (M. L. Koschinsky, J. E. Tomlinson, T. F. Zioncheck, K. Schwartz, D. L. Eaton and R. M. Lawn, submitted for publication). Carbohydrate composition and isoelectric focusing analyses indicate that the recombinant molecule is highly glycosylated and negatively charged, as is its natural counterpart, and retains the lysine binding properties of Lp(a). Availability of this pure molecule allows us to investigate the effect of the apo(a) protein on ligand interaction unencumbered by the problems of working with the plasma-derived lipoprotein, such as aggregation and purity. Furthermore, the recombinant-derived apo(a) need not be subject to the reducing conditions utilized to purify it from the Lp(a) lipoprotein, avoiding partial denaturation and misfolding, which appear to affect some of its binding properties. A sis, has > 90% of lysine residues modified, and binds to mouse peritoneal macrophages, as determined by the manufacturer. LDL and Lp(a) (isoform size of its apo(a) -700,000 D) were purified to homogeneity (as determined by silver stained 4-15% denaturing polyacrylamide gels) from human plasma by NaBr and CsCl density gradient centrifugation (12) and plasminogen was purified by lysine-Sepharose chromatography ( 13) . LDL and Lp(a) preparations were stored at 4'C in 7.5% Apo(a), Lp(a), and acetyl LDL were biotinylated using biotin-N-hydroxysuccinimide ester (Calbiochem-Behring Corp., La Jolla, CA) with a ratio ofbiotin ester to protein of 1:2.5. A form ofapo(a) containing 17 copies of the kringle four-like domain and single copies of its domains which resemble kringle five and the protease of plasminogen was produced in cultured human kidney-derived cells by recombinant DNA techniques and purified to homogeneity (as defined by the presence ofa single band in silver-stained SDS-PAGE) by either lysine-Sepharose or monoclonal antibody chromatography (M. L. Koschinsky, J. E. Tomlinson, T. F. Zioncheck, K. Schwartz, D. L. Eaton, and R. M. Lawn, submitted for publication). Protein concentrations determined by the method of Bradford (14) .
P388D. 1 cells were grown to subconfluence in RPMI-1640 (Gibco, Grand Island, NY) plus I mM L-glutamine and 10% heat-inactivated FBS and harvested by physical dislodging (15) . Approximately 5 x 105 cells were incubated with biotinylated substrates in a total volume of 50 ,ul ofPBS containing 2% FBS for 1 h on ice. The cells were washed twice with PBS plus 2% FBS and stained in a similar manner with phycoerythrin conjugated streptavidin (CalTag, South San Francisco, CA). Flow cytometry analysis was performed on either a modified Coulter Electronics 753 (Hialeah, FL) or a Becton Dickinson FACscan (Mountain View, CA) using standard excitation and emission parameters for phycoerythrin ( 16) .
Binding of '25I-apo(a) to P388D. I cells. Recombinant apo(a) was iodinated to a specific activity of 3.5 x 106 cpm/,ug with Iodo-beads (Pierce Chemical Co., Rockford, IL) according to the manufacturer's suggested procedure. Labeled and unlabeled apo(a) were made 10% in FBS and then dialyzed against RPMI-1640 before incubation with p388D.1 cells. I07 macrophages were added at 4°C to an incubation mixture containing 10`' M '251I-apo(a) and a range ofunlabeled apo(a) concentrations. Incubations were carried out for 2 h in 12 x 75 mm Falcon tubes which were shaken gently every 10 min to maintain cells in suspension. Cell bound '251-apo(a) was separated from unbound by overlaying an aliquot of the incubation mixture on a 1 -ml cushion of FBS chilled to 4°C. Cells were pelleted through the FBS by centrifugation at 2,900 g for 1 min in a microfuge. Supematants were aspirated and cell pellets were counted in a gamma counter to determine counts bound. Free radioactivity was determined by subtracting bound from total counts. Nonspecific binding in the presence of 100 to 5,000-fold molar excess ofunlabeled apo(a) accounted for -25% oftotal binding, and was subtracted to yield the values of specific binding shown.
Results
Analysis of the interaction of biotinylated acetyl LDL with P388D. 1 cells using the technique of laser scan flow cytometry showed specific binding with concentrations as low as 10 nM biotinylated acetyl LDL (Fig. 1 a) . Our results obtained with flow cytometry are comparable to those previously reported by Via and colleagues using iodinated acetyl LDL (15) . Specificity was demonstrated by competition with nonbiotinylated acetyl LDL. A 50-fold molar excess ofapo(a) effectively prevented the binding of biotinylated acetyl LDL as well. This result prompted the analysis of the binding of biotinylated apo(a) and Lp(a) to P388D. 1 cells. Biotinylated apo(a) binding was detectable at concentrations of 500 ng/ml (1 nM) and saturated at -50 ug/ml (100 nM) (Fig. 1 b) . The binding ofbiotinylated apo(a) was dramatically reduced in the presence of excess apo(a), implying specificity. Binding of biotinylated Lp(a) displayed a similar dose dependence (not shown). The binding of apo(a) was markedly inhibited by acetyl LDL but not significantly by plasminogen (Fig. 1 c) . Similarly, the binding of the biotinylated lipoprotein Lp(a) was competed by apo(a) and acetyl LDL, but not by LDL or plasminogen (Fig. 2  a) . (Due to aggregation, binding of biotinylated apo(a), as opposed to Lp(a), appeared to be partially inhibited by LDL.) It seems likely that labeling procedures employed here did not modify the binding characteristics of ligands, because the binding of labeled apo(a) and acetyl LDL is effectively competed for by the unlabeled ligand. We also observed that apo(a) was more potent competitor of labeled acetyl LDL binding than acetyl LDL itself (Fig. 2 b) . This higher avidity could be due to the many copies of glycosylated kringle domains present in each molecule of apo(a), and suggests that different isoforms of apo(a) may vary in their binding.
To quantitate the binding of apo(a), the interaction of radioiodinated r-apo(a) with cells was analyzed. '25I-labeled apo(a), like the biotinylated protein, has specific and saturable binding to P388D. 1 cells (Fig. 3) ( 15) .
Functional binding ofacetyl LDL to macrophages results in uptake and degradation in lysosomes. To determine whether apo(a) could be metabolized by macrophages iodinated rapo(a) was incubated with P388D. 1 cells at 37°C in the presence or absence of unlabeled excess r-apo(a). As shown in Fig. 4 a, increasing concentrations of iodinated apo(a) produced an increase in acid-soluble label in the media, with saturation at -40 nM. Chloroquine inhibited the response, suggesting that degradation occurred in lysozomes (17) . However, the relative rate of degradation of apo(a) was about one-fourth of that observed with acetyl LDL (Fig. 4 b) . Thus, we conclude that macrophages are capable of limited uptake and degradation of apo(a) bound at 37°C.
Discussion
Previous reports have suggested that native Lp(a) does not significantly interact with human monocyte-derived or mouse peritoneal macrophages (18, 19 (26) (27) (28) . This suggests that elevated Lp(a) might interfere with fibrinolysis at the cellular level. This result is intriguing when combined with the observation that Lp(a) does not substantially inhibit clot lysis in the fluid phase (27, 29) (although some reports disagree with that analysis [30, 31] ). Hence, the nearly 25% of the population with Lp(a) levels in the increased risk range do not appear to have gross clotting abnormalities, but may possess increased residual thrombi at the surface of blood vessels which could lead to the gradual development of atherosclerotic lesions.
Lp(a) might also be localized to damaged vessel walls by binding to components of cell matrix or blood clots such as fibronectin (32) or fibrin (33) . Lp(a) has been detected in the intima of atherosclerotic lesions by immunohistochemistry and by the measurement of protein extracted from tissue (34, 35 sis by a number of effects which include foam cell formation and the induction ofgrowth factors, release ofarachidonic acid metabolites and increased procoagulant activity (10, 36, 37, 38) . In view of Lp(a)'s potency as a risk factor for this major disease, it remains important to further characterize the interaction of Lp(a) with macrophages and other cells and macromolecules that are present in the artery wall.
